首页 > 最新文献

Critical Reviews in Therapeutic Drug Carrier Systems最新文献

英文 中文
Exploring the Therapeutic Potential of Anticancer Heterocyclic Compounds: Role in Nanoscale Pharmacotherapy. 探索抗癌杂环化合物的治疗潜力:在纳米级药物治疗中的作用。
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2022039548
Lalit Kumar, Shivani Verma, Kajal Joshi, Sumit Sharma

There are a large number of pharmaceutical products in the market containing heterocyclic compounds. Heterocyclic compounds are explored in the field of therapeutics due to their unique physicochemical and pharmacological properties. A large number of heterocyclic compounds existing in the pharmaceutical market have marked anticancer activity and many of them are under research investigations to treat different types of cancers. Anticancer heterocyclic compounds show many shortcomings such as other anticancer agents in bioavailability and site-specific drug delivery resulting in toxicity and decreased patient compliance. These shortcomings can be eliminated by applying the principles of nanotechnology. The present review discloses the biochemical mechanism of action, different biological targets, intrinsic shortcomings, and structure-activity relationships of anticancer heterocyclic compounds. Furthermore, the role of different nanocarrier systems in selective biological targeting and alteration of pharmacokinetic and pharmacodynamic characteristics of anticancer heterocyclic compounds will be discussed in detail.

市场上有大量含有杂环化合物的药品。杂环化合物以其独特的物理化学和药理性质在治疗学领域得到了广泛的应用。医药市场上存在的大量杂环化合物具有显著的抗癌活性,其中许多化合物正在进行研究,以治疗不同类型的癌症。抗癌杂环化合物在生物利用度和部位特异性给药方面存在许多缺点,导致毒性和患者依从性降低。这些缺点可以通过应用纳米技术的原理来消除。本文综述了抗癌杂环化合物的生物化学作用机制、不同的生物学靶点、内在缺陷以及构效关系。此外,还将详细讨论不同纳米载体系统在抗癌杂环化合物的选择性生物靶向和药代动力学及药效学特性改变中的作用。
{"title":"Exploring the Therapeutic Potential of Anticancer Heterocyclic Compounds: Role in Nanoscale Pharmacotherapy.","authors":"Lalit Kumar,&nbsp;Shivani Verma,&nbsp;Kajal Joshi,&nbsp;Sumit Sharma","doi":"10.1615/CritRevTherDrugCarrierSyst.2022039548","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2022039548","url":null,"abstract":"<p><p>There are a large number of pharmaceutical products in the market containing heterocyclic compounds. Heterocyclic compounds are explored in the field of therapeutics due to their unique physicochemical and pharmacological properties. A large number of heterocyclic compounds existing in the pharmaceutical market have marked anticancer activity and many of them are under research investigations to treat different types of cancers. Anticancer heterocyclic compounds show many shortcomings such as other anticancer agents in bioavailability and site-specific drug delivery resulting in toxicity and decreased patient compliance. These shortcomings can be eliminated by applying the principles of nanotechnology. The present review discloses the biochemical mechanism of action, different biological targets, intrinsic shortcomings, and structure-activity relationships of anticancer heterocyclic compounds. Furthermore, the role of different nanocarrier systems in selective biological targeting and alteration of pharmacokinetic and pharmacodynamic characteristics of anticancer heterocyclic compounds will be discussed in detail.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"40 3","pages":"47-94"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9228614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Plant-based approaches for rheumatoid arthritis regulation: Mechanistic insights on pathogenesis, molecular pathways and delivery systems 植物性类风湿关节炎的调控方法:发病机制、分子通路和传递系统的机制见解
4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.1615/critrevtherdrugcarriersyst.2023048324
Anita Bhoi, Shradha Devi Dwivedi, Deependra Singh, Sahu Keshavkant, Manju Singh
Purpose: Rheumatoid Arthritis (RA) is classified as a chronic inflammatory autoimmune disorder that is associated with a varied range of immunological changes, synovial hyperplasia, cartilage destructions, as well as bone erosion. Even though many conventional drugs are suggested by a medical practitioner such as DMARDs, NSAIDs, glucocorticoids, etc. to treat RA, but, they have allied with various side effects. Therefore, this study tries to compile the most recent research on how plant-based compounds/nano-formulations can combat RA with minimal or no adverse effects. Methods: Databases including Google, Science Direct, Google Scholar, Web of Science, PubMed, Scopus, and Research Gate have been looked through for potentially existing research with the goal of discovering the latest progress on multiple viewpoints of phyto-compounds over RA. Results: In order to decrease the generation of pro-inflammatory cytokines, many phyto-compounds have been reported that regulate cell cycle arrest, FLS proliferation, autophagy, apoptosis, and numerous signaling pathways. Also, the therapeutic difficulties and clinical usefulness of nano-delivery systems are investigated. Conclusions: A tailored approach for treating inflamed tissue may possibly improve the therapeutic efficacy of the drug while reducing its systemic adverse effects. Additionally, the growing herbal revolution has led to the invention of new methods for delivering poorly soluble herbal bioactives and plant extracts to improve their efficacy at targeted inflamed synovial sites.
目的:类风湿关节炎(RA)被归类为一种慢性炎症性自身免疫性疾病,与各种免疫变化、滑膜增生、软骨破坏以及骨侵蚀有关。尽管医生建议许多常规药物如DMARDs、非甾体抗炎药、糖皮质激素等治疗类风湿性关节炎,但它们都有各种副作用。因此,本研究试图汇编关于植物基化合物/纳米制剂如何在最小或没有副作用的情况下对抗类风湿性关节炎的最新研究。方法:通过Google、Science Direct、Google Scholar、Web of Science、PubMed、Scopus、Research Gate等数据库查找潜在的现有研究,从多个角度发现植物化合物治疗类风湿性关节炎的最新进展。结果:为了减少促炎细胞因子的产生,许多植物化合物被报道可以调节细胞周期阻滞、FLS增殖、自噬、凋亡和许多信号通路。此外,研究了纳米递送系统的治疗困难和临床用途。结论:治疗炎症组织的量身定制方法可能提高药物的治疗效果,同时减少其全身不良反应。此外,不断发展的草药革命已经导致了新方法的发明,用于输送难溶性草药生物活性物质和植物提取物,以提高其在靶向炎症滑膜部位的功效。
{"title":"Plant-based approaches for rheumatoid arthritis regulation: Mechanistic insights on pathogenesis, molecular pathways and delivery systems","authors":"Anita Bhoi, Shradha Devi Dwivedi, Deependra Singh, Sahu Keshavkant, Manju Singh","doi":"10.1615/critrevtherdrugcarriersyst.2023048324","DOIUrl":"https://doi.org/10.1615/critrevtherdrugcarriersyst.2023048324","url":null,"abstract":"Purpose: Rheumatoid Arthritis (RA) is classified as a chronic inflammatory autoimmune disorder that is associated with a varied range of immunological changes, synovial hyperplasia, cartilage destructions, as well as bone erosion. Even though many conventional drugs are suggested by a medical practitioner such as DMARDs, NSAIDs, glucocorticoids, etc. to treat RA, but, they have allied with various side effects. Therefore, this study tries to compile the most recent research on how plant-based compounds/nano-formulations can combat RA with minimal or no adverse effects. Methods: Databases including Google, Science Direct, Google Scholar, Web of Science, PubMed, Scopus, and Research Gate have been looked through for potentially existing research with the goal of discovering the latest progress on multiple viewpoints of phyto-compounds over RA. Results: In order to decrease the generation of pro-inflammatory cytokines, many phyto-compounds have been reported that regulate cell cycle arrest, FLS proliferation, autophagy, apoptosis, and numerous signaling pathways. Also, the therapeutic difficulties and clinical usefulness of nano-delivery systems are investigated. Conclusions: A tailored approach for treating inflamed tissue may possibly improve the therapeutic efficacy of the drug while reducing its systemic adverse effects. Additionally, the growing herbal revolution has led to the invention of new methods for delivering poorly soluble herbal bioactives and plant extracts to improve their efficacy at targeted inflamed synovial sites.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"36 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135495872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exosomes: Recent Advances and Challenges as Targeted Therapeutic Delivery Vesicles. 外泌体:作为靶向治疗递送囊泡的最新进展和挑战。
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2022044495
Sourabh Jadhav, Ankaj Kumar, Arvind Gulbake

The exosome is a naturally derived nanostructured lipid vesicle that ranges from 40-100 nm in size and is utilized to transport drugs, and biological macromolecules, including therapeutic RNA and proteins. It is a membrane vesicle actively released by cells to transport cellular components with a purpose for biological events. The conventional isolation technique has several drawbacks, including low integrity, low purity, long processing time, and sample preparation. Therefore, microfluidic technologies are more widely accepted for the isolation of pure exosomes, but due to cost and expertise requirements, this technology is also facing challenges. The bioconjugation of small and macro-molecules to the surface of exosomes is a very interesting and emerging approach for achieving the specific target, therapeutic purpose, in vivo imaging, and many more. Although emerging strategies resolve a few challenges, exosomes are still unexplored complex nano-vesicles with excellent properties. This review has briefly elaborated on contemporary isolation techniques and loading approaches. We have also discussed the surface-modified exosomes by different conjugation methods and their applications as targeted drug delivery vesicles. The challenges associated with the exosomes, patents, and clinical investigations are the main highlight of this review.

外泌体是一种天然衍生的纳米结构脂质囊泡,大小在40-100纳米之间,用于运输药物和生物大分子,包括治疗性RNA和蛋白质。它是一种由细胞主动释放的膜泡,用于运输细胞成分,以达到生物事件的目的。传统的分离技术存在完整性低、纯度低、处理时间长、样品制备困难等缺点。因此,微流控技术在分离纯外泌体方面被广泛接受,但由于成本和专业知识的要求,该技术也面临着挑战。小分子和大分子外泌体表面的生物偶联是一种非常有趣和新兴的方法,用于实现特定靶点,治疗目的,体内成像等。尽管新兴的策略解决了一些挑战,但外泌体仍然是尚未开发的具有优异性能的复杂纳米囊泡。这篇综述简要阐述了当代隔离技术和加载方法。我们还讨论了不同缀合方法的表面修饰外泌体及其作为靶向药物递送囊泡的应用。与外泌体、专利和临床研究相关的挑战是本综述的主要亮点。
{"title":"Exosomes: Recent Advances and Challenges as Targeted Therapeutic Delivery Vesicles.","authors":"Sourabh Jadhav,&nbsp;Ankaj Kumar,&nbsp;Arvind Gulbake","doi":"10.1615/CritRevTherDrugCarrierSyst.2022044495","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2022044495","url":null,"abstract":"<p><p>The exosome is a naturally derived nanostructured lipid vesicle that ranges from 40-100 nm in size and is utilized to transport drugs, and biological macromolecules, including therapeutic RNA and proteins. It is a membrane vesicle actively released by cells to transport cellular components with a purpose for biological events. The conventional isolation technique has several drawbacks, including low integrity, low purity, long processing time, and sample preparation. Therefore, microfluidic technologies are more widely accepted for the isolation of pure exosomes, but due to cost and expertise requirements, this technology is also facing challenges. The bioconjugation of small and macro-molecules to the surface of exosomes is a very interesting and emerging approach for achieving the specific target, therapeutic purpose, in vivo imaging, and many more. Although emerging strategies resolve a few challenges, exosomes are still unexplored complex nano-vesicles with excellent properties. This review has briefly elaborated on contemporary isolation techniques and loading approaches. We have also discussed the surface-modified exosomes by different conjugation methods and their applications as targeted drug delivery vesicles. The challenges associated with the exosomes, patents, and clinical investigations are the main highlight of this review.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"40 4","pages":"101-133"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9475167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Narrative Review on Non-Invasive Drug Delivery of Teriparatide: A Ray of Hope. 特立帕肽无创给药研究述评:一线希望。
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2023045480
Neeraj Mittal, Gajanand Sharma, Om Parkash Katare, Sanjay Kumar Bhadada

In the field of pharmaceutical biotechnology and formulation development, various protein and peptide-based drugs have been used for therapeutic and clinical implications. These are mainly given via parenteral routes like intravenous, subcutaneous or intramuscular delivery. Teriparatide, also known as PTH 1-34, is a U.S. Food & Drug Administartion-approved anabolic drug to treat osteoporosis is currently available in market only as subcutaneous injection. The quest for elimination of needle in case of given peptidal delivery to replace it with alternative routes like nasal, buccal, transdermal and pulmonary pathways has driven meticulous drug research. The pharmaceutical scientists are working on innovation and approaches involving new materials and methods to develop the formulations for protein and peptides by noninvasive routes. Lately, various approaches have been carried out which involve many strategies and technologies to deliver teriparatide via alternative routes. But, physicochemical instability, proteolytic degradation, low bioavailability, etc. are some obstacles to develop suitable delivery system for teriparatide. This review intends to gather the overall developments in delivery systems specific to teriparatide which meant for better convenience and avoids vulnerability of multiple subcutaneous injections. In addition, the article emphasizes on the successes to develop noninvasive technologies and devices, and new milestones for teriparatide delivery.

在制药生物技术和配方开发领域,各种蛋白质和肽基药物已被用于治疗和临床意义。这些药物主要通过静脉、皮下或肌肉注射等非肠外途径给药。特立帕肽,也被称为PTH 1-34,是美国食品和药物管理局批准的治疗骨质疏松症的合成代谢药物,目前在市场上仅作为皮下注射。在给药的情况下,寻求消除针头,代之以鼻、口腔、透皮和肺部等替代途径,已经推动了细致的药物研究。制药科学家正致力于创新和方法,包括新材料和新方法,通过非侵入性途径开发蛋白质和肽的配方。最近,已经采取了各种方法,其中涉及许多战略和技术,通过其他途径提供三立帕肽。但是,特立帕肽的理化不稳定性、蛋白水解降解、生物利用度低等问题是开发合适的特立帕肽给药系统的障碍。本综述旨在收集特立帕肽特异性给药系统的总体发展,这意味着更好的便利性和避免多次皮下注射的脆弱性。此外,文章还强调了非侵入性技术和设备的成功发展,以及特立帕肽给药的新里程碑。
{"title":"A Narrative Review on Non-Invasive Drug Delivery of Teriparatide: A Ray of Hope.","authors":"Neeraj Mittal,&nbsp;Gajanand Sharma,&nbsp;Om Parkash Katare,&nbsp;Sanjay Kumar Bhadada","doi":"10.1615/CritRevTherDrugCarrierSyst.2023045480","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2023045480","url":null,"abstract":"<p><p>In the field of pharmaceutical biotechnology and formulation development, various protein and peptide-based drugs have been used for therapeutic and clinical implications. These are mainly given via parenteral routes like intravenous, subcutaneous or intramuscular delivery. Teriparatide, also known as PTH 1-34, is a U.S. Food & Drug Administartion-approved anabolic drug to treat osteoporosis is currently available in market only as subcutaneous injection. The quest for elimination of needle in case of given peptidal delivery to replace it with alternative routes like nasal, buccal, transdermal and pulmonary pathways has driven meticulous drug research. The pharmaceutical scientists are working on innovation and approaches involving new materials and methods to develop the formulations for protein and peptides by noninvasive routes. Lately, various approaches have been carried out which involve many strategies and technologies to deliver teriparatide via alternative routes. But, physicochemical instability, proteolytic degradation, low bioavailability, etc. are some obstacles to develop suitable delivery system for teriparatide. This review intends to gather the overall developments in delivery systems specific to teriparatide which meant for better convenience and avoids vulnerability of multiple subcutaneous injections. In addition, the article emphasizes on the successes to develop noninvasive technologies and devices, and new milestones for teriparatide delivery.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"40 6","pages":"117-140"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10019094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the Therapeutic Potential of Cyclosporine for Ophthalmic Indications by Novel Carrier Systems. 利用新型载体系统探索环孢素治疗眼科适应症的潜力。
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2022043085
Garima Rawat, Shital Kolhe, Dhwani Rana, Sagar Salave, Derajram Benival

Cyclosporine (CsA) stays the most intangible molecule holding a good history for treating several ophthalmic conditions and it even attributes to multiple off-label uses. Topical delivery of CsA is the most preferred route but owing to the molecule's physicochemical properties such as poor aqueous solubility and high molecular weight as well as its encounter with multiple barriers of eye causes hindrance for proper delivery of the molecule to the site of action. However, Restasis®, Cequa®, and Verkazia® are the marketed formulations that have been approved by U.S. Food and Drug Administration, whereas Cyclokat® and Ikervis® by the European Medicines Agency. Although these medications are in use, they are associated with severe discomfort and poor patient compliance. This review gives an overview regarding current formulations available in the market, the products in pipeline and the recent advances undertaken for improving ocular delivery of CsA for various ophthalmic indications.

环孢素(CsA)一直是最无形的分子,在治疗几种眼科疾病方面有着良好的历史,它甚至被归为多种标签外用途。局部给药CsA是最优选的途径,但由于分子的物理化学性质,如水溶性差和高分子量,以及遇到多重眼屏障,导致分子无法正确递送到作用部位。然而,Restasis®,Cequa®和Verkazia®是已获美国食品和药物管理局批准的上市制剂,而Cyclokat®和Ikervis®则是由欧洲药品管理局批准的。虽然这些药物正在使用,但它们与严重不适和患者依从性差有关。这篇综述概述了目前市场上可用的配方、正在开发的产品以及最近为改善针对各种眼科适应症的CsA眼部输送所进行的进展。
{"title":"Exploring the Therapeutic Potential of Cyclosporine for Ophthalmic Indications by Novel Carrier Systems.","authors":"Garima Rawat,&nbsp;Shital Kolhe,&nbsp;Dhwani Rana,&nbsp;Sagar Salave,&nbsp;Derajram Benival","doi":"10.1615/CritRevTherDrugCarrierSyst.2022043085","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2022043085","url":null,"abstract":"<p><p>Cyclosporine (CsA) stays the most intangible molecule holding a good history for treating several ophthalmic conditions and it even attributes to multiple off-label uses. Topical delivery of CsA is the most preferred route but owing to the molecule's physicochemical properties such as poor aqueous solubility and high molecular weight as well as its encounter with multiple barriers of eye causes hindrance for proper delivery of the molecule to the site of action. However, Restasis®, Cequa®, and Verkazia® are the marketed formulations that have been approved by U.S. Food and Drug Administration, whereas Cyclokat® and Ikervis® by the European Medicines Agency. Although these medications are in use, they are associated with severe discomfort and poor patient compliance. This review gives an overview regarding current formulations available in the market, the products in pipeline and the recent advances undertaken for improving ocular delivery of CsA for various ophthalmic indications.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"40 5","pages":"1-45"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9901985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Impact of Nanotechnology on Differentiation and Augmentation of Stem Cells for Liver Therapy. 纳米技术对肝治疗干细胞分化和增强的影响。
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2023042400
Ifrah Anwar, Usman Ali Ashfaq

The liver is one of the crucial organs of the body that performs hundreds of chemical reactions needed by the body to survive. It is also the largest gland of the body. The liver has multiple functions, including the synthesis of chemicals, metabolism of nutrients, and removal of toxins. It also acts as a storage unit. The liver has a unique ability to regenerate itself, but it can lead to permanent damage if the injury is beyond recovery. The only possible treatment of severe liver damage is liver transplant which is a costly procedure and has several other drawbacks. Therefore, attention has been shifted towards the use of stem cells that have shown the ability to differentiate into hepatocytes. Among the numerous kinds of stem cells (SCs), the mesenchymal stem cells (MSCs) are the most famous. Various studies suggest that an MSC transplant can repair liver function, improve the signs and symptoms, and increase the chances of survival. This review discusses the impact of combining stem cell therapy with nanotechnology. By integrating stem cell science and nanotechnology, the information about stem cell differentiation and regulation will increase, resulting in a better comprehension of stem cell-based treatment strategies. The augmentation of SCs with nanoparticles has been shown to boost the effect of stem cell-based therapy. Also, the function of green nanoparticles in liver therapies is discussed.

肝脏是人体至关重要的器官之一,它执行人体生存所需的数百种化学反应。它也是人体最大的腺体。肝脏有多种功能,包括化学物质的合成、营养物质的代谢和毒素的排除。它还可以作为存储单元。肝脏具有独特的自我再生能力,但如果损伤无法恢复,它可能导致永久性损伤。严重肝损伤的唯一可能的治疗方法是肝移植,这是一个昂贵的过程,并且有几个其他的缺点。因此,人们的注意力已经转移到干细胞的使用上,这些干细胞已经显示出分化为肝细胞的能力。在种类繁多的干细胞(SCs)中,以间充质干细胞(MSCs)最为著名。各种研究表明,MSC移植可以修复肝功能,改善体征和症状,并增加生存机会。本文综述了将干细胞治疗与纳米技术相结合的影响。通过整合干细胞科学和纳米技术,关于干细胞分化和调控的信息将会增加,从而更好地理解基于干细胞的治疗策略。纳米颗粒增强SCs已被证明可以提高干细胞治疗的效果。此外,还讨论了绿色纳米颗粒在肝脏治疗中的作用。
{"title":"Impact of Nanotechnology on Differentiation and Augmentation of Stem Cells for Liver Therapy.","authors":"Ifrah Anwar,&nbsp;Usman Ali Ashfaq","doi":"10.1615/CritRevTherDrugCarrierSyst.2023042400","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2023042400","url":null,"abstract":"<p><p>The liver is one of the crucial organs of the body that performs hundreds of chemical reactions needed by the body to survive. It is also the largest gland of the body. The liver has multiple functions, including the synthesis of chemicals, metabolism of nutrients, and removal of toxins. It also acts as a storage unit. The liver has a unique ability to regenerate itself, but it can lead to permanent damage if the injury is beyond recovery. The only possible treatment of severe liver damage is liver transplant which is a costly procedure and has several other drawbacks. Therefore, attention has been shifted towards the use of stem cells that have shown the ability to differentiate into hepatocytes. Among the numerous kinds of stem cells (SCs), the mesenchymal stem cells (MSCs) are the most famous. Various studies suggest that an MSC transplant can repair liver function, improve the signs and symptoms, and increase the chances of survival. This review discusses the impact of combining stem cell therapy with nanotechnology. By integrating stem cell science and nanotechnology, the information about stem cell differentiation and regulation will increase, resulting in a better comprehension of stem cell-based treatment strategies. The augmentation of SCs with nanoparticles has been shown to boost the effect of stem cell-based therapy. Also, the function of green nanoparticles in liver therapies is discussed.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"40 6","pages":"89-116"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10019091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lignin-Based Nanomaterials as Drug Delivery Vehicles: A Review. 木质素基纳米药物递送载体研究进展
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2022041829
Tahmidul Islam Aquib

Over the past decade, lignin-based nanomaterials have astonishingly gained tremendous popularity among researchers worldwide for utilization in various high-value added fields. However, the copiousness of published articles suggests that lignin-based nanomaterials are currently being given the most priority as drug delivery vehicles or drug carriers. A large number of reports have been published during the past decade reporting successful application of lignin nanoparticles as drug carrier, not only for drugs administered in human but also for drugs used in plants such as pesticides, fungicides, etc. In this review, all of these reports have been discussed in an elaborate fashion so as to present all the available information pertaining to the application of lignin-based nanomaterials in drug delivery in a comprehensive manner.

在过去的十年中,木质素基纳米材料在各种高附加值领域得到了广泛的应用。然而,大量发表的文章表明,木质素基纳米材料目前作为药物递送载体或药物载体被给予了最优先的考虑。在过去的十年中,木质素纳米颗粒作为药物载体的成功应用已经发表了大量的报道,不仅用于人体给药,而且用于植物中使用的药物,如杀虫剂、杀菌剂等。在这篇综述中,所有这些报告都以一种详细的方式进行了讨论,以便全面地介绍有关木质素基纳米材料在药物传递中的应用的所有可用信息。
{"title":"Lignin-Based Nanomaterials as Drug Delivery Vehicles: A Review.","authors":"Tahmidul Islam Aquib","doi":"10.1615/CritRevTherDrugCarrierSyst.2022041829","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2022041829","url":null,"abstract":"<p><p>Over the past decade, lignin-based nanomaterials have astonishingly gained tremendous popularity among researchers worldwide for utilization in various high-value added fields. However, the copiousness of published articles suggests that lignin-based nanomaterials are currently being given the most priority as drug delivery vehicles or drug carriers. A large number of reports have been published during the past decade reporting successful application of lignin nanoparticles as drug carrier, not only for drugs administered in human but also for drugs used in plants such as pesticides, fungicides, etc. In this review, all of these reports have been discussed in an elaborate fashion so as to present all the available information pertaining to the application of lignin-based nanomaterials in drug delivery in a comprehensive manner.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"40 4","pages":"1-67"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9475174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Review on Recent Advances in Mannose-Functionalized Targeted Nanocarrier Delivery Systems in Cancer and Infective Therapeutics. 甘露糖功能化靶向纳米载体递送系统在癌症和感染治疗中的最新进展。
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2022041853
Vasanti Suvarna, Niserga Sawant, Namita Desai

Unmodified nanocarriers used in the chemotherapy of cancers and various infectious diseases exhibit prolonged blood circulation time, prevent enzymatic degradation and increase chemical stability of encapsulated therapeutics. However, off-target effect and lack of specificity associated with unmodified nanoparticles (NPs) limit their applications in the health care system. Mannose (Man) receptors with significant overexpression on antigen-presenting cells and macrophages are among the most admired targets for cancer and anti-infective therapeutics. Therefore, development of Man functionalized nanocarriers targeting Man receptors, for target specific drug delivery in the chemotherapy have been extensively studied. Present review expounds diverse Man-conjugated NPs with their potential for targeted drug delivery, improved biodistribution profiles and localization. Additionally, the review gives detailed account of the interactions of mannosylated NPs with various biological systems and their characterization not discussed in earlier published reports is discussed.

未经修饰的纳米载体用于癌症和各种传染病的化疗,具有延长血液循环时间,防止酶降解和提高包封治疗药物化学稳定性的特点。然而,与未修饰纳米颗粒(NPs)相关的脱靶效应和缺乏特异性限制了它们在医疗保健系统中的应用。甘露糖(Man)受体在抗原呈递细胞和巨噬细胞上显著过表达,是癌症和抗感染治疗中最受欢迎的靶点之一。因此,开发靶向Man受体的Man功能化纳米载体,用于化疗中的靶向特异性药物递送已被广泛研究。本文综述了不同的人偶联NPs及其在靶向给药、改善生物分布和定位方面的潜力。此外,该综述还详细介绍了甘露糖基化NPs与各种生物系统的相互作用,并讨论了之前发表的报告中未讨论的特性。
{"title":"A Review on Recent Advances in Mannose-Functionalized Targeted Nanocarrier Delivery Systems in Cancer and Infective Therapeutics.","authors":"Vasanti Suvarna,&nbsp;Niserga Sawant,&nbsp;Namita Desai","doi":"10.1615/CritRevTherDrugCarrierSyst.2022041853","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2022041853","url":null,"abstract":"<p><p>Unmodified nanocarriers used in the chemotherapy of cancers and various infectious diseases exhibit prolonged blood circulation time, prevent enzymatic degradation and increase chemical stability of encapsulated therapeutics. However, off-target effect and lack of specificity associated with unmodified nanoparticles (NPs) limit their applications in the health care system. Mannose (Man) receptors with significant overexpression on antigen-presenting cells and macrophages are among the most admired targets for cancer and anti-infective therapeutics. Therefore, development of Man functionalized nanocarriers targeting Man receptors, for target specific drug delivery in the chemotherapy have been extensively studied. Present review expounds diverse Man-conjugated NPs with their potential for targeted drug delivery, improved biodistribution profiles and localization. Additionally, the review gives detailed account of the interactions of mannosylated NPs with various biological systems and their characterization not discussed in earlier published reports is discussed.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"40 2","pages":"43-82"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9228684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Advances in Current Drugs and Formulations for the Management of Atopic Dermatitis. 目前治疗特应性皮炎的药物及配方研究进展。
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2023042979
Keerthi Atluri, Srikanth Manne, Vijendra Nalamothu, Alon Mantel, Purnendu K Sharma, R Jayachandra Babu

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease with a complex pathophysiology. Treatment of AD remains challenging owing to the presence of a wide spectrum of clinical phenotypes and limited response to existing therapies. However, recent genetic, immunological, and pathophysiological insights into the disease mechanism resulted in the invention of novel therapeutic drug candidates. This review provides a comprehensive overview of current therapies and assesses various novel drug delivery strategies currently under clinical investigation. Further, this review majorly emphasizes on various topical treatments including emollient therapies, barrier repair agents, topical corticosteroids (TCS), phosphodiesterase 4 (PDE4) inhibitors, calcineurin inhibitors, and Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway inhibitors. It also discusses biological and systemic therapies, upcoming treatments based on ongoing clinical trials. Additionally, this review scrutinized the use of pharmaceutical inactive ingredients in the approved topical dosage forms for AD treatment.

特应性皮炎(AD)是一种慢性、复发性炎症性皮肤病,具有复杂的病理生理。由于存在广泛的临床表型和对现有疗法的有限反应,阿尔茨海默病的治疗仍然具有挑战性。然而,最近对疾病机制的遗传、免疫学和病理生理学见解导致了新的候选治疗药物的发明。这篇综述提供了目前治疗的全面概述,并评估了目前正在临床研究的各种新的给药策略。此外,本综述主要侧重于各种局部治疗,包括润肤疗法、屏障修复剂、局部皮质类固醇(TCS)、磷酸二酯酶4 (PDE4)抑制剂、钙调磷酸酶抑制剂和Janus激酶(JAK)信号转导和转录激活因子(STAT)途径抑制剂。它还讨论了基于正在进行的临床试验的生物和全身治疗,即将进行的治疗。此外,本综述审查了在已批准的用于AD治疗的外用剂型中药物非活性成分的使用。
{"title":"Advances in Current Drugs and Formulations for the Management of Atopic Dermatitis.","authors":"Keerthi Atluri,&nbsp;Srikanth Manne,&nbsp;Vijendra Nalamothu,&nbsp;Alon Mantel,&nbsp;Purnendu K Sharma,&nbsp;R Jayachandra Babu","doi":"10.1615/CritRevTherDrugCarrierSyst.2023042979","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2023042979","url":null,"abstract":"<p><p>Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease with a complex pathophysiology. Treatment of AD remains challenging owing to the presence of a wide spectrum of clinical phenotypes and limited response to existing therapies. However, recent genetic, immunological, and pathophysiological insights into the disease mechanism resulted in the invention of novel therapeutic drug candidates. This review provides a comprehensive overview of current therapies and assesses various novel drug delivery strategies currently under clinical investigation. Further, this review majorly emphasizes on various topical treatments including emollient therapies, barrier repair agents, topical corticosteroids (TCS), phosphodiesterase 4 (PDE4) inhibitors, calcineurin inhibitors, and Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway inhibitors. It also discusses biological and systemic therapies, upcoming treatments based on ongoing clinical trials. Additionally, this review scrutinized the use of pharmaceutical inactive ingredients in the approved topical dosage forms for AD treatment.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"40 6","pages":"1-87"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10010645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent Advances and Prospects for Plant Gum-Based Drug Delivery Systems: A Comprehensive Review. 植物胶基给药系统的研究进展与展望
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2022042252
Minkal Tuteja, Kalpana Nagpal

This work is an effort to first introduce plant-based gums and discussing their drug delivery applications. The composition of these plant gums and their major characteristics, which make them suitable as pharmaceutical excipients are also described in detail. The various modifications methods such as physical and chemical modifications of gums and polysaccharides have been discussed along with their applications in different fields. Consequently, plant-based gums modification such as etherification and grafting is attracting much scientific attention to satisfy industrial demand. The evaluation tests to characterize gum-based drug delivery systems have been summarized. The release behavior of drug from plant-gum-based drug delivery is being discussed. Thus, this review is an attempt to critically summarize different aspect of plant-gum-based polysaccharides to be utilized in drug delivery systems having potential industrial applications.

这项工作是首次介绍植物性牙龈并讨论其给药应用。还详细介绍了这些植物胶的组成及其适合作为药用辅料的主要特性。讨论了树胶和多糖的各种改性方法,如物理改性和化学改性,以及它们在不同领域的应用。因此,以植物为基础的胶基改性,如醚化和接枝,正在引起越来越多的科学关注,以满足工业需求。综述了牙龈基给药系统的评价试验。本文讨论了植物胶基给药过程中药物的释放行为。因此,本综述试图批判性地总结植物胶基多糖在具有潜在工业应用的药物输送系统中的不同方面。
{"title":"Recent Advances and Prospects for Plant Gum-Based Drug Delivery Systems: A Comprehensive Review.","authors":"Minkal Tuteja,&nbsp;Kalpana Nagpal","doi":"10.1615/CritRevTherDrugCarrierSyst.2022042252","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2022042252","url":null,"abstract":"<p><p>This work is an effort to first introduce plant-based gums and discussing their drug delivery applications. The composition of these plant gums and their major characteristics, which make them suitable as pharmaceutical excipients are also described in detail. The various modifications methods such as physical and chemical modifications of gums and polysaccharides have been discussed along with their applications in different fields. Consequently, plant-based gums modification such as etherification and grafting is attracting much scientific attention to satisfy industrial demand. The evaluation tests to characterize gum-based drug delivery systems have been summarized. The release behavior of drug from plant-gum-based drug delivery is being discussed. Thus, this review is an attempt to critically summarize different aspect of plant-gum-based polysaccharides to be utilized in drug delivery systems having potential industrial applications.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"40 2","pages":"83-124"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9228679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Critical Reviews in Therapeutic Drug Carrier Systems
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1